Innovent Biologics (China), a clinical stage biotechnology company focused on the development of monoclonal antibodies targeting various diseases, closed a $25M Series B financing. Participants include Lilly Asia Ventures, Fidelity Biosciences and Fidelity Growth Partners Asia.